Global Vaccine Adjuvants Market Expected to Reach $1.32 billion by 2026
The Global Vaccine Adjuvants Market was valued at US$517.74 million in the year 2018 and is expected to cross US$1.32 billion by the end of 2026, with a healthy CAGR of 12.5%. Increasing Prevalence of cancer, infectious and zoonotic diseases, and more focus by governments and policymakers across the globes in curbing diseases on a large scale, by introducing vaccination programs, increasing use of adjuvants in vaccine to increase the antigenicity, technological advancements in healthcare and launch of new vaccines are expected to chiefly drive the vaccine adjuvants market through the forecast period. Besides, the cost involved in identifying the ideal adjuvant molecule, side-effects, stringent regulatory policies imposed by the government, stability issues and lack of effectiveness of adjuvants is identified as the restraints that can hamper the growth of the vaccine adjuvants market.
Adjuvants help vaccines to work better and enhance the body’s immune response. The adjuvants aids in producing an overt immune response against a disease type. Yet, the adjuvants can trigger local immunological reactions such as swelling, rashes and pain, and systemic immunological reactions such as fever, chills, and body aches. Many case studies have been carried out by vaccine scientists and governments across the globe to adjudge that vaccines and vaccine adjuvants are safe for humans. Recently, the focus from short-term vaccination had shifted in developing vaccines that offer protection and boost the immune response for a longer period. The research on identifying novel vaccine adjuvants are also underway since the existing adjuvants offer inadequate immunogenicity and are becoming ineffective. Moreover, the increase in investments by companies in research and development, increasing focus on immunization programs, and growing demand for vaccines are fueling the growth of the market. Besides, the use of synthetic and recombinant vaccines also expected to bolster the growth of vaccine adjuvants market during the forecast period.
North America holds a dominant position in the market in terms of revenue, due to the high adoption of innovations and the local presence of major market players in this region. Especially, the US contributes more as the market is driven by the increasing geriatric population, rising incidences of diseases, rising investments in R&D for developing new therapeutics, rising government funding, and increasing focus on immunization programs. Thus, the increased geriatric population in the region results in increased demand for vaccine adjuvants.
Europe is the second-largest market owing to increasing emphasis and availability of funds for research and development activities that are carried out in the biotechnological and pharmaceutical industries to introduce highly effective vaccines to tackle chronic diseases. Also, recent policy changes across EU countries where vaccination is becoming mandatory for infant and adolescent population is expected to enhance the market growth to a greater extent.
Besides, the Asia Pacific region is also expected to witness significant growth, owing to the presence of a large population that is prone to various chronic and infectious diseases, including influenza and cancer. Therefore, the introduction of innovative vaccine adjuvants will provide better solutions to patients at marginally lower costs. Hence, the market is expected to grow at a rapid pace.
The particulate adjuvants held the major market share in 2018. The particulate adjuvant type accounts for alum, cytokines, and virosomes. Alum is the most commonly used adjuvant that consists of aluminum salts. It is used in hepatitis B and HPV vaccines. Virosomes that are particles resembling noninfectious viruses are used as adjuvants in hepatitis A, Epaxal and influenza vaccine Inflexal. On the other hand, the pathogen type segment is expected to be the fastest-growing segment during the forecast period.
Mostly, the vaccine comprising adjuvants is administered intramuscularly, though the route of administration can be oral, intradermal, intranasal, etc. The effect of vaccines is elucidated based on the route of administration. In recent times, intradermal administration of the vaccine is mostly preferred as the absorption time and the bioavailability is more comparatively. Intradermal administration is mostly preferred for the administration of vaccines for infectious diseases.
Infectious diseases accounted for the largest market share that can be attributed to diseases like influenza, malaria, hepatitis, etc. Currently, there is avid research underway to identify novel adjuvants. Companies such as Merck, GSK, Agenus, Vaxine are investing more in research & development. Also, the companies are looking forward to expanding their market presence through collaborations, mergers, and acquisitions. For example, in 2019, Croda International acquired Brenntag Biosector for 72 million Euros and also acquired German-based Rewitec. Few companies are also involved in developing novel infant vaccines.
Optima Insights Vaccine Adjuvants Market Outlook 2019-2026, will offer a thorough understanding of the market growth through the forecast period, 2019-2026. We have segmented the market based on the Disease Type, Route of Administration, Application, Product Type and Region (North America, Europe, APAC & LAMEA). The report comprises comprehensive profiling of 17 companies developing vaccine adjuvants, including GSK, Merck, Sanofi, Croda International, Avanti Polar Lipids, Adjuvatis, Novavax, and Immunovative Therapies Ltd.
Vaccine Adjuvants Market Based on Product Type (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
- Pathogen Components
- Adjuvant Emulsions
- Combination Adjuvants
- Particulate Adjuvants
Vaccine Adjuvants Market Based on Route of Administration (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
Vaccine Adjuvants Market Based on Disease Type (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
- Infectious diseases
Vaccine Adjuvants Market Based on Application (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
- Commercial applications
Vaccine Adjuvants Market Based on Application Categories (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
- Human vaccine adjuvants
- Veterinary vaccine adjuvants
Vaccine Adjuvants Market Based on End-User (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
Vaccine Adjuvants Market Based on Geographic Region (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)
- North America
Vaccine Adjuvants Market Competitive Analysis (Company Overview, SWOT Matrix, Financial, Product Overview, and Market Strategies)
- Sanofi S.A
- Croda International
- Avanti Polar Lipids
- Immunovative Therapies Ltd
- Provides detailed Analysis of the Market Structure along with forecast of the various segments and sub-segments.
- Provides a Comparative Analysis of Key Marketed and Pipeline Products.
- Provides Key Information on Players involved.
- Provides a Complete Overview of Market Segments and the Regional Outlook.
- Provides In-depth Coverage of Key News, including Major Mergers, Acquisitions and Product Development updates such as clinical trial progression updates and regulatory updates.
The Report Provides Key Insights on
- History of the Vaccine Adjuvants Market, 2015 to 2017
- Forecast of the Vaccine Adjuvants Market Growth till the year 2026
- The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the Vaccine Adjuvants Market
- Analysis of potential growth segments which will drive the market
- Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market
- Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics
Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global Vaccine Adjuvants and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to take better business decisions towards attaining market leadership.
Mr Chucks G
+91 966 6620 365 (Asia) | +1 424 2554 365 (US)